Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT03485092
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 105 participants
- Registry
-
NCT03485092
-
- Other papers using this trial's data
- Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03485092. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-16 (actual); primary completion 2020-03-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
- Acronym
- SUGAR-DM-HF
- Condition
- Heart Failure
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Collaborator
- University of Glasgow
Record details
- Record id
cardio:ct-nct03485092- Content hash
12549386753f18d01608dbccf4eea278072e4520bf8a60bbcd5c7c7798bd19e5